Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 11

Results For "Eli-Lilly"

123 News Found

David Kendall named Zealand Pharma CMO
People | June 03, 2022

David Kendall named Zealand Pharma CMO

Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy


Eugia Pharma receives USFDA approval for Pemetrexed
Drug Approval | May 26, 2022

Eugia Pharma receives USFDA approval for Pemetrexed

Pemetrexed for injection is indicated for the treatment of Antineoplastics (medications used to treat cancer)


Tirzepatide has potential to drive weight loss market dramatically, observes GlobalData
Biotech | May 15, 2022

Tirzepatide has potential to drive weight loss market dramatically, observes GlobalData

Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022


USFDA approves novel, dual-targeted treatment for type 2 diabetes
Drug Approval | May 15, 2022

USFDA approves novel, dual-targeted treatment for type 2 diabetes

In clinical trials, treatment proved more effective than other therapies evaluated


Increased prevalence of diabetes and product innovation to boost insulin pens market in India, says GlobalData
News | May 13, 2022

Increased prevalence of diabetes and product innovation to boost insulin pens market in India, says GlobalData

India has the second-largest number of adults with diabetes globally, after China


USFDA approves Lilly and Incyte's Olumiant to treat hospitalised patients with Covid-19
Drug Approval | May 12, 2022

USFDA approves Lilly and Incyte's Olumiant to treat hospitalised patients with Covid-19

Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19


Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity
Biotech | April 29, 2022

Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity

Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study


Telix Pharmaceuticals announces licence agreement with Lilly for olaratumab
Biotech | April 11, 2022

Telix Pharmaceuticals announces licence agreement with Lilly for olaratumab

Lilly may be eligible for up to US $ 225m in payments based upon the achievement of pre-specified development, regulatory and commercial milestones


Clinical Trials in the New Normal
Opinion | March 24, 2022

Clinical Trials in the New Normal

The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay


Jardiance is first and only treatment approved in Europe for chronic heart failure
Drug Approval | March 07, 2022

Jardiance is first and only treatment approved in Europe for chronic heart failure

The breakthrough approval expands the existing indication of Jardiance to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe